Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease
Vaccination has become an important therapeutic approach to the treatment of Alzheimer's disease (AD), however, immunization with Aβ amyloid can have unwanted, potentially lethal, side effects. Here we demonstrate an alternative peptide-mimotope vaccine strategy using the SDPM1 peptide. SDPM1 i...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-09-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996110001646 |
id |
doaj-e011341541e548d38efeaaa05a0a3207 |
---|---|
record_format |
Article |
spelling |
doaj-e011341541e548d38efeaaa05a0a32072021-03-20T04:59:36ZengElsevierNeurobiology of Disease1095-953X2010-09-01393409422Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's diseaseChiou-Miin Wang0Sarah deVries1Marybeth Camboni2Matthew Glass3Paul T. Martin4Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USACenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USACenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USACenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USACenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA; Department of Pediatrics, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA; Department of Physiology and Cell Biology, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA; Corresponding author. Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Ohio State University College of Medicine, 700 Children's Drive, Columbus, OH 43205, USA. Fax: +1 614 722 5893.Vaccination has become an important therapeutic approach to the treatment of Alzheimer's disease (AD), however, immunization with Aβ amyloid can have unwanted, potentially lethal, side effects. Here we demonstrate an alternative peptide-mimotope vaccine strategy using the SDPM1 peptide. SDPM1 is a 20 amino acid peptide bounded by cysteines that binds tetramer forms of Aβ1–40- and Aβ1–42-amyloids and blocks subsequent Aβ amyloid aggregation. Immunization of mice with SDPM1 induced peptide-mimotope antibodies with the same biological activity as the SDPM1 peptide. When done prior to the onset of amyloid plaque formation, SDPM1 vaccination of APPswePSEN1(A246E) transgenic mice reduced amyloid plaque burden and Aβ1–40 and Aβ1–42 levels in the brain, improved cognitive performance in Morris water maze tests, and resulted in no increased T cell responses to immunogenic or Aβ peptides or brain inflammation. When done after plaque burden was already significant, SDPM1 immunization still significantly reduced amyloid plaque burden and Aβ1–40/1–42 peptide levels in APPswePSEN1(A246E) brain without inducing encephalitogenic T cell responses or brain inflammation, but treatment at this stage did not improve cognitive function. These experiments demonstrate the efficacy of a novel vaccine approach for Alzheimer's disease where immunization with an Aβ1–40/1–42 amyloid-specific binding and blocking peptide is used to inhibit the development of neuropathology and cognitive dysfunction.http://www.sciencedirect.com/science/article/pii/S0969996110001646Alzheimer's diseaseAgingDementiaVaccinePeptide mimotopeMemory |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chiou-Miin Wang Sarah deVries Marybeth Camboni Matthew Glass Paul T. Martin |
spellingShingle |
Chiou-Miin Wang Sarah deVries Marybeth Camboni Matthew Glass Paul T. Martin Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease Neurobiology of Disease Alzheimer's disease Aging Dementia Vaccine Peptide mimotope Memory |
author_facet |
Chiou-Miin Wang Sarah deVries Marybeth Camboni Matthew Glass Paul T. Martin |
author_sort |
Chiou-Miin Wang |
title |
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
title_short |
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
title_full |
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
title_fullStr |
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
title_full_unstemmed |
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease |
title_sort |
immunization with the sdpm1 peptide lowers amyloid plaque burden and improves cognitive function in the appswepsen1(a246e) transgenic mouse model of alzheimer's disease |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
2010-09-01 |
description |
Vaccination has become an important therapeutic approach to the treatment of Alzheimer's disease (AD), however, immunization with Aβ amyloid can have unwanted, potentially lethal, side effects. Here we demonstrate an alternative peptide-mimotope vaccine strategy using the SDPM1 peptide. SDPM1 is a 20 amino acid peptide bounded by cysteines that binds tetramer forms of Aβ1–40- and Aβ1–42-amyloids and blocks subsequent Aβ amyloid aggregation. Immunization of mice with SDPM1 induced peptide-mimotope antibodies with the same biological activity as the SDPM1 peptide. When done prior to the onset of amyloid plaque formation, SDPM1 vaccination of APPswePSEN1(A246E) transgenic mice reduced amyloid plaque burden and Aβ1–40 and Aβ1–42 levels in the brain, improved cognitive performance in Morris water maze tests, and resulted in no increased T cell responses to immunogenic or Aβ peptides or brain inflammation. When done after plaque burden was already significant, SDPM1 immunization still significantly reduced amyloid plaque burden and Aβ1–40/1–42 peptide levels in APPswePSEN1(A246E) brain without inducing encephalitogenic T cell responses or brain inflammation, but treatment at this stage did not improve cognitive function. These experiments demonstrate the efficacy of a novel vaccine approach for Alzheimer's disease where immunization with an Aβ1–40/1–42 amyloid-specific binding and blocking peptide is used to inhibit the development of neuropathology and cognitive dysfunction. |
topic |
Alzheimer's disease Aging Dementia Vaccine Peptide mimotope Memory |
url |
http://www.sciencedirect.com/science/article/pii/S0969996110001646 |
work_keys_str_mv |
AT chioumiinwang immunizationwiththesdpm1peptidelowersamyloidplaqueburdenandimprovescognitivefunctionintheappswepsen1a246etransgenicmousemodelofalzheimersdisease AT sarahdevries immunizationwiththesdpm1peptidelowersamyloidplaqueburdenandimprovescognitivefunctionintheappswepsen1a246etransgenicmousemodelofalzheimersdisease AT marybethcamboni immunizationwiththesdpm1peptidelowersamyloidplaqueburdenandimprovescognitivefunctionintheappswepsen1a246etransgenicmousemodelofalzheimersdisease AT matthewglass immunizationwiththesdpm1peptidelowersamyloidplaqueburdenandimprovescognitivefunctionintheappswepsen1a246etransgenicmousemodelofalzheimersdisease AT paultmartin immunizationwiththesdpm1peptidelowersamyloidplaqueburdenandimprovescognitivefunctionintheappswepsen1a246etransgenicmousemodelofalzheimersdisease |
_version_ |
1724211498611376128 |